Navigation Links
Boston Scientific Announces Results For Second Quarter Ended June 30, 2013
Date:7/25/2013

place undue reliance on any of our forward-looking statements.

Risks and uncertainties that may cause such differences include, among other things: future economic, political, competitive, reimbursement and regulatory conditions; new product introductions and the market acceptance of those products; markets for our products; expected pricing environment; expected procedural volumes; clinical trial results; demographic trends; intellectual property rights; litigation; financial market conditions; the execution and effect of our restructuring program; the execution and effect of our business strategy, including our cost-savings and growth initiatives; and future business decisions made by us and our competitors. New risks and uncertainties may arise from time to time and are difficult to predict. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control.
For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item IA - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter.
We disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.
This cautionary statement is applicable to all forward-looking statements contained in this press release.

Use of Non-GAAP Financial InformationA reconciliation of the company's non-GAAP financial measures to the corresponding GAAP measures, and an explanation of the company's use of these non
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. American Laboratory Trading Continues Steady Growth with Expansion in Boston
2. Affordable Scrum Training in Boston,MA by Conscires Agile Practices
3. Formedix CEO Invited to Speak at OpenClinica Global Conference in Boston
4. The 2013 Bioprocessing Summit to Bring Together International Leaders to Discuss Today's Bioprocess Issues From Cell Line Selection to Manufacturing in Boston, MA
5. Verified Clinical Trials (VCT) Will Co-Present With SAFE-BioPharma At Bio-IT World April 10th In Boston, MA Exploring Identity Management In eClinical Trials
6. Boston Heart Diagnostics Awarded $450,000 in Tax Incentives from the Massachusetts Life Sciences Center
7. Local Leaders Convene in Boston to Share Industry Best Practices in Second “Business of Big Data” Summit
8. R&D, Innovation Key to Success - Research Report on Varian Medical Systems, Inc., Boston Scientific Corporation, Stryker Corporation, St. Jude Medical, Inc., and Thermo Fischer Scientific Inc.
9. Boston College researchers unique nanostructure produces novel plasmonic halos
10. Boston Scientific to Webcast Conference Call Discussing Fourth Quarter and Full Year 2012 Financial Results on January 29th
11. Shire and Boston Childrens Hospital Enter Into Broad Research Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... , July 1, 2015 R-Japan Co.,Ltd. obtained the ... Safety of Regenerative Medicine from the Ministry of Health, Labour ... 29, 2015. The fact that R- ... through the auditing from Pharmaceuticals and Medical Devices Agency (PMDA) ... allows it to provide stem cell manufacturing service to medical ...
(Date:6/30/2015)... June 30, 2015  Juniper Pharmaceuticals, Inc. (Nasdaq: ... developing therapeutics that address unmet medical needs in ... Elston will present at the Cantor Fitzgerald ... 8, 2015Time: , 4:45 PM EDTLocation: , Le ... archive): , www.juniperpharma.com, under  ,Investor, or  ...
(Date:6/30/2015)... ... ... The maximum number of shares proposed to be purchased in the tender ... restricted stock). On June 29, 2015, the last trading day prior to the commencement ... OTCBB was $2.29 per share. , The tender offer will expire on July 28, ...
(Date:6/30/2015)... , June 30, 2015  The Dr. Samadi Prostate ... is now offering a full suite of new genetic testing ... a biopsy, for diagnosing prostate cancer. ... of genetic tests for assessing the risk and optimizing the ... "We,re very excited to now offer these revolutionary genetic ...
Breaking Biology Technology:R-Japan Obtained Autologous Stem Cell Manufacturing License from the Ministry of Health, Labour and Welfare 2Juniper Pharmaceuticals to Present at Cantor Fitzgerald Inaugural Healthcare Conference on July 8, 2015 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 3New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 2New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 3New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 4New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 5
... , WAYNE, N.J., Sept. 24 ... of Surgery and Director of Coronary Surgery and Advanced Coronary ... has completed the world,s first use of the MAQUET Minimized ... endoscopic heart surgery. The new cardiopulmonary bypass technology is the ...
... , SALT LAKE CITY, Sept. ... through the development of molecular diagnostics, announced today that its ... spine specialists in the United States. SCOLISCORE is a saliva-based ... scoliosis, an abnormal lateral curvature of the spine. Spine surgeons ...
... /PRNewswire-Asia-FirstCall/ --, -- Q4 FY 2009 Revenues increased 43.2% to ... $2.2 Million with diluted EPS of $0.08, -- FY 2009 ... Increased 32.4% to $7.9 Million vs. FY08 with diluted EPS of ... to $8.3 Million, -- June 30, 2009 Cash and equivalents ...
Cached Biology Technology:MAQUET Cardiovascular Announces Leading Robotic Heart Surgeon Performs First Beating Heart Fully Endoscopic Bypass Surgery Using Miniaturized Cardiopulmonary Bypass System 2MAQUET Cardiovascular Announces Leading Robotic Heart Surgeon Performs First Beating Heart Fully Endoscopic Bypass Surgery Using Miniaturized Cardiopulmonary Bypass System 3MAQUET Cardiovascular Announces Leading Robotic Heart Surgeon Performs First Beating Heart Fully Endoscopic Bypass Surgery Using Miniaturized Cardiopulmonary Bypass System 4Axial Biotech Announces Commercial Availability of SCOLISCORE(TM) AIS Prognostic Test 2Axial Biotech Announces Commercial Availability of SCOLISCORE(TM) AIS Prognostic Test 3Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 2Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 3Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 4Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 5Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 6Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 7Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 8Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 9Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 10Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 11Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 12
(Date:6/16/2015)... 16, 2015 /CNW Telbec/ - handyem Inc. and ... the incorporation of handyem,s HPC-150 portable flow cytometer ... Mo-POD™. This unprecedented model of mobile laboratory platform ... the Pennsylvania Convention Center, ... th to 18 th 2015.  By ...
(Date:6/15/2015)... June 16, 2015 According to ... by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, ... 2020" published by MarketsandMarkets, The Natural Language Processing Market ... CAGR of 18.4% for the forecast period 2015-2020. ... 46 F igures spread   through 155 P ...
(Date:6/11/2015)... 2015 Daon, a global leader in ... IdentityX Mobile Authentication Platform v4.0 has been FIDO ... an industry consortium launched in 2013 to revolutionize ... authentication.  In order to receive certification, a company,s ... of tests that measure compliance and ensure interoperability ...
Breaking Biology News(10 mins):handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3Natural Language Processing Market Worth $13.4 Billion by 2020 2Natural Language Processing Market Worth $13.4 Billion by 2020 3Natural Language Processing Market Worth $13.4 Billion by 2020 4Natural Language Processing Market Worth $13.4 Billion by 2020 5Daon's IdentityX Mobile Authentication Platform One of First Products to be Certified by FIDO Alliance 2
... and Harvard Medical School have shown how a key ... triggering other changes that allow the AIDS virus to ... Feb. 24 issue of the journal Nature, offer clues ... Researchers led by Howard Hughes Medical Institute Investigator Stephen ...
... human embryonic,stem cells have been contaminated with a ... human subjects,according to research by investigators at the ... and the Salk Institute in La Jolla,California.,In a ... journal Nature,Medicine, the researchers found that human embryonic ...
... available. However, a,similar and equally dangerous addiction, alcoholism, ... be? Researchers from the University of,California in San ... addiction in rodents. We can only hope that ... close future; it would help fix a,problem that ...
Cached Biology News:Elusive HIV shape change revealed; Key clue to how virus infects cells 2Current human embryonic stem cell lines contaminated UCSD/Salk team finds 2Current human embryonic stem cell lines contaminated UCSD/Salk team finds 3Current human embryonic stem cell lines contaminated UCSD/Salk team finds 4Controversial drug shown to act on brain protein to cut alcohol use 2Controversial drug shown to act on brain protein to cut alcohol use 3
Adhesive seal-tab, for HybriWell™ hybridization sealing system *set of 400*...
...
... Platypus Contact Printing Kit contains choice of ... series of 100 / 200 micron squares ... 200 um x 10 mm lines, 3 ... 40 or 60 nm and pitch of ...
...
Biology Products: